Clinical Trial

RGL-305+ Lymphoma + Exploratory Clinical Study

Recruiting
View on ClinicalTrials.gov →
Summary
This study is an open, prospective, dose-increasing exploratory clinical trial. To evaluate the safety, cytodynamics and initial efficacy of RGL-305 in patients with lymphoma. All enrolled lymphoma patients were required to achieve CR or PR and MRD positive after standard treatment, PR patients were required to have a Deauville score of 4, and all patients would receive RGL-305 cell reinfusion therapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-28.
Trial Details
NCT Number NCT07006012
Lead Sponsor Fudan University
Conditions Lymphoma Patients With Complete Response (CR) or Partial Response (PR) After Standard Treatment Had a Positive Minimal Residual Lesion (MRD)
Enrollment 12 participants
Start Date 2025-04-21
Primary Completion 2028-03-31 (estimated)
Study Completion 2031-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-24